XV Eurasian Hematology-Oncology Congress - EHOC 2024

 

XV Eurasian Hematology-Oncology Congress - EHOC 2024
Avatar

Novel Agents in the Treatment of R/R CLL

By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Nitin Jain
By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Nitin Jain
41 views
October 9, 2024

Chapters

Decade of CLL Target Therapy & Recent Approvals

00:00

Treatment Sequencing Scenarios in CLL

01:38

Transition from Ibrutinib to Second-Gen BTK Inhibitors

03:54

Pirtobrutinib Approval & Resistance Challenges

05:51

CAR-T Liso-cel Approval & PFS Analysis

10:21

Emerging CLL Therapies & BTK Degraders

12:17

Comments 0
Login to view comments. Click here to Login
Leukemia
22:08

Pediatric ALL: Etiology, Diagnosis and Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

O. TüFekçI GüRocak

14 views
23:50

CML Case Discussion: Elderly Patients not Meeting ELN Milestones

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Isam Sharif

7 views
15:42

New

CLL Case: Acquired Del(17p) at Relapse

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Özer Çerme

03:40

New

ALL Case: B-ALL Arising During Len Maintenance in Myeloma Patient

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Ozsoy

15:34

Novel Agents in the Treatment of R/R CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

41 views
17:52

Venetoclax-Based Regimens in AML: Understanding Resistance and Devel…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

93 views
16:58

Targeted Therapies in AML With a Focus on FLT3 Inhibitors

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

31 views
22:58

A Clinical Case of Extranodal MZL of the Palatum Durum After CLL/SLL…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Ridova

6 views
12:18

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

135 views
17:45

Ph+ ALL Management: Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Koruk

15 views
17:37

AML Case Discussion: FLT3-ITD+ High-Risk Disease

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Hindilerden

20 views
18:32

Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With …

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

37 views
15:51

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

19 views
20:29

TKI Discontinuation in CML: Defining Eligibility Criteria and Predic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Yassin

22 views
07:49

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

12 views
15:14

Critical Re-Evaluation of Established Practices in CML Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

151 views
28:43

Management of R/R AML: Treatment Options and Case Insights

XV Eurasian Hematology-Oncology Congress - EHOC 2024

V. Bonuomo

39 views
19:01

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

599 views
14:17

Practical Approach to MRD Monitoring in AML: Assessing Treatment Eff…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

96 views
10:30

Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Hoelzer

27 views
09:06

Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patie…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

37 views
23:52

CLL Case Discussion: First Line Treatment Strategies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Ortaboz

51 views
18:01

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

206 views
18:49

CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Erdogan

12 views
17:13

The Importance of MRD in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

162 views
22:26

Management of AML in Older Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

198 views
34:29

Current Approaches to Managing T-Cell ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

19 views
15:10

TKI Toxicity Management in CML: A Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Alshurafa

20 views
18:56

Management of Persistently MRD+ ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Odabasi Giden

27 views
18:07

Debates in AML: 3+7 is the SOC Induction Therapy for AML

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Uzay

52 views
11:33

Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-An…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Sarici

31 views
16:19

Current Options for Finite-Duration Therapy With BTKis in CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

148 views